Brief: Viracta Therapeutics Says Complete Responses Observed Across Multiple Ebv+ Lymphoma Subtypes In Phase 2 Study

Viracta Therapeutics

07/12/2020 11:55

Dec 7 (Reuters) - Viracta Therapeutics :
    * VIRACTA THERAPEUTICS - COMPLETE RESPONSES OBSERVED ACROSS
MULTIPLE EBV+ LYMPHOMA SUBTYPES IN PHASE 2 STUDY 
    * VIRACTA THERAPEUTICS - REGISTRATION TRIAL FOR TREATMENT OF
RELAPSED/REFRACTORY EBV+ LYMPHOMAS TO BEGIN IN 1H2021
    * VIRACTA THERAPEUTICS - END OF PHASE 2 MEETING WITH UNITED
STATES
FDA TO ADDRESS CHEMISTRY, MANUFACTURING AND CONTROLS IS PLANNED
FOR DEC 2020

Source : https://bit.ly/3mWycvK

 ((Reuters.Briefs@thomsonreuters.com;))